BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/7/2026 9:40:23 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-02-13 02:50 |
|
Peer-Review Started |
|
2026-02-13 02:54 |
|
First Decision by Editorial Office Director |
|
2026-03-04 09:11 |
|
Return for Revision |
|
2026-03-06 09:56 |
|
Revised |
|
2026-03-31 18:51 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-20 02:56 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-20 06:51 |
|
Articles in Press |
|
2026-04-20 06:51 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-30 12:33 |
|
Publish the Manuscript Online |
|
2026-08-07 09:40 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Evidence Review |
| Article Title |
Bridging the intraductal papillary mucinous neoplasm risk stratification gap: A critical review of current and emerging biomarkers
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Peter Mačinga, Jiří Zahradník, Tomáš Hucl and Radoslav Janoštiak |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Czech Health Research Council |
NU23J-06-00043 |
| Charles University PRIMUS Program |
PRIMUS/22/MED/007 |
| European Union-Next Generation EU, Programme EXCELES |
LX22NPO5102 |
|
| Corresponding Author |
Radoslav Janoštiak, Associate Professor, PhD, Professor, BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, Vestec 25250, Czech Republic. radoslav.janostiak@lf1.cuni.cz |
| Key Words |
Pancreatic cancer; Intraductal papillary mucinous neoplasms; Biomarker; Risk stratification; Cyst fluid; Liquid biopsy |
| Core Tip |
Current guidelines for intraductal papillary mucinous neoplasm management inadequately distinguish indolent lesions from high grade dysplasia, resulting in both overtreatment and missed cancer. This evidence review critically examines established and emerging circulating and cyst fluid biomarkers, including molecular, inflammatory, and glycoprotein markers. We emphasize diagnostic performance, methodological limitations, and translational barriers. We highlight the impact of pooled histological endpoints, small surgical cohorts, assay heterogeneity, and lack of multicenter validation on the accuracy of the current studies. Finally, we outline the requirements needed to clinically integrate these biomarkers into intraductal papillary mucinous neoplasm risk stratification. |
| Publish Date |
2026-08-07 09:40 |
| Citation |
Mačinga P, Zahradník J, Hucl T, Janoštiak R. Bridging the intraductal papillary mucinous neoplasm risk stratification gap: A critical review of current and emerging biomarkers. World J Gastrointest Oncol 2026; 18(8): 120019
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i8/120019.htm |
| DOI |
https://doi.org/10.4251/wjgo.120019 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
